Cosmetic cross-reference Noindex: medium evidence

Heptane

CAS 142-82-5

Heptane (CAS 142-82-5) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Heptane
CAS Number
142-82-5
UNII
456148SDMJ
InChIKey
IMNFDUFMRHMDMM-UHFFFAOYSA-N
ChEMBL ID
CHEMBL134658
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE RxNorm drug names 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
HEPTANE 2472186 SU MTHSPL
heptane 2472186 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Heptane used for in pharmaceutical contexts?

Heptane (CAS 142-82-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Heptane?

No adverse-event association or SIDER side-effect rows are rendered for Heptane in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Heptane also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Heptane with EU status "permitted".

What clinical phase is Heptane in?

No phase 1-4 clinical development badge is rendered for Heptane because the matched compound identifier rows do not contain a max-phase value.